Cabaletta Bio, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2021

Financial Assets Measured at Fair Value on Recurring Basis

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:

	December 31, 2021
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial assets
Cash and cash equivalents:
Money market funds	$	122,222	$	122,222	$	—	$	—
Total	$	122,222	$	122,222	$	—	$	—

	December 31, 2020
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial assets
Cash and cash equivalents:
Money market funds	$	101,429	$	101,429	$	—	$	—
Short-term investments:
Corporate bonds		7,233		—		7,233		—
Total	$	108,662	$	101,429	$	7,233	$	—

Schedule of Debt Securities Classified as Available-for-Sale Investments

	December 31, 2020
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair value
Financial assets
Money market funds
Included in cash and cash equivalents	$	101,429	$	—	$	—	$	101,429
Corporate bonds - due in one year or less
Included in short-term investments		7,227		6		—		7,233
Total	$	108,656	$	6	$	—	$	108,662